• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Nat Cell Biol . A single-cell transcriptomic landscape of the lungs of patients with COVID-19

tetano

Editor, Senior Moderator
Nat Cell Biol


. 2021 Dec 7.
doi: 10.1038/s41556-021-00796-6. Online ahead of print.
A single-cell transcriptomic landscape of the lungs of patients with COVID-19


Si Wang[SUP] #[/SUP][SUP] 1 2 [/SUP], Xiaohong Yao[SUP] #[/SUP][SUP] 3 4 [/SUP], Shuai Ma[SUP] #[/SUP][SUP] 1 5 [/SUP], Yifang Ping[SUP] #[/SUP][SUP] 3 4 [/SUP], Yanling Fan[SUP] #[/SUP][SUP] 6 [/SUP], Shuhui Sun[SUP] #[/SUP][SUP] 1 [/SUP], Zhicheng He[SUP] #[/SUP][SUP] 3 4 [/SUP], Yu Shi[SUP] #[/SUP][SUP] 3 4 [/SUP], Liang Sun[SUP] #[/SUP][SUP] 7 8 9 [/SUP], Shiqi Xiao[SUP] #[/SUP][SUP] 3 4 [/SUP], Moshi Song[SUP] #[/SUP][SUP] 1 5 10 [/SUP], Jun Cai[SUP] 11 [/SUP], Jiaming Li[SUP] 6 10 [/SUP], Rui Tang[SUP] 3 4 [/SUP], Liyun Zhao[SUP] 2 [/SUP], Chaofu Wang[SUP] 12 [/SUP], Qiaoran Wang[SUP] 6 10 [/SUP], Lei Zhao[SUP] 11 [/SUP], Huifang Hu[SUP] 10 13 [/SUP], Xindong Liu[SUP] 3 4 [/SUP], Guoqiang Sun[SUP] 10 13 [/SUP], Lu Chen[SUP] 3 4 [/SUP], Guoqing Pan[SUP] 8 [/SUP], Huaiyong Chen[SUP] 14 [/SUP], Qingrui Li[SUP] 3 4 [/SUP], Peipei Zhang[SUP] 12 15 [/SUP], Yuanyuan Xu[SUP] 3 4 [/SUP], Huyi Feng[SUP] 16 [/SUP], Guo-Guang Zhao[SUP] 2 17 [/SUP], Tianzi Wen[SUP] 3 4 [/SUP], Yungui Yang[SUP] 5 6 10 [/SUP], Xuequan Huang[SUP] 18 [/SUP], Wei Li[SUP] 5 10 13 [/SUP], Zhenhua Liu[SUP] 19 [/SUP], Hongmei Wang[SUP] 5 10 13 [/SUP], Haibo Wu[SUP] 15 [/SUP], Baoyang Hu[SUP] 5 10 13 [/SUP], Yong Ren[SUP] 20 [/SUP], Qi Zhou[SUP] 5 10 13 [/SUP], Jing Qu[SUP] 21 22 23 [/SUP], Weiqi Zhang[SUP] 24 25 26 27 [/SUP], Guang-Hui Liu[SUP] 28 29 30 31 [/SUP], Xiu-Wu Bian[SUP] 32 33 [/SUP]



Affiliations

Abstract

The lung is the primary organ targeted by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), making respiratory failure a leading coronavirus disease 2019 (COVID-19)-related mortality. However, our cellular and molecular understanding of how SARS-CoV-2 infection drives lung pathology is limited. Here we constructed multi-omics and single-nucleus transcriptomic atlases of the lungs of patients with COVID-19, which integrate histological, transcriptomic and proteomic analyses. Our work reveals the molecular basis of pathological hallmarks associated with SARS-CoV-2 infection in different lung and infiltrating immune cell populations. We report molecular fingerprints of hyperinflammation, alveolar epithelial cell exhaustion, vascular changes and fibrosis, and identify parenchymal lung senescence as a molecular state of COVID-19 pathology. Moreover, our data suggest that FOXO3A suppression is a potential mechanism underlying the fibroblast-to-myofibroblast transition associated with COVID-19 pulmonary fibrosis. Our work depicts a comprehensive cellular and molecular atlas of the lungs of patients with COVID-19 and provides insights into SARS-CoV-2-related pulmonary injury, facilitating the identification of biomarkers and development of symptomatic treatments.
 
Back
Top Bottom